156 related articles for article (PubMed ID: 38238578)
41. Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas.
Minor DR; Kim KB; Karuturi RKM; Kashani-Sabet M
Front Oncol; 2023; 13():1241917. PubMed ID: 38111529
[TBL] [Abstract][Full Text] [Related]
42. Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.
Chatziioannou E; Leiter U; Thomas I; Keim U; Seeber O; Meiwes A; Boessenecker I; Gonzalez SS; Torres FM; Niessner H; Sinnberg T; Forschner A; Flatz L; Amaral T
Am J Clin Dermatol; 2023 May; 24(3):453-467. PubMed ID: 37142875
[TBL] [Abstract][Full Text] [Related]
43. Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
Richtig E; Ludwig R; Kerl H; Smolle J
Br J Dermatol; 2005 Nov; 153(5):925-31. PubMed ID: 16225601
[TBL] [Abstract][Full Text] [Related]
44. Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.
Ismail RK; Suijkerbuijk KPM; de Boer A; van Dartel M; Hilarius DL; Pasmooij AMG; van Zeijl MCT; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; de Groot JWB; Haanen JBAG; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; van der Veldt AAM; Vreugdenhil A; Westgeest H; van den Eertwegh AJ; Wouters MWJM
Melanoma Res; 2022 Dec; 32(6):460-468. PubMed ID: 35703270
[TBL] [Abstract][Full Text] [Related]
45. Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.
Rohaan MW; Stahlie EHA; Franke V; Zijlker LP; Wilgenhof S; van der Noort V; van Akkooi ACJ; Haanen JBAG
BMC Cancer; 2022 Aug; 22(1):851. PubMed ID: 35927710
[TBL] [Abstract][Full Text] [Related]
46. End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study.
van Breeschoten J; Ismail RK; Wouters MWJM; Hilarius DL; de Wreede LC; Haanen JB; Blank CU; Aarts MJB; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Stevense-den Boer MA; van der Veldt AAM; Vreugdenhil G; Boers-Sonderen MJ; Suijkerbuijk KPM; van den Eertwegh AJM
JCO Oncol Pract; 2022 Oct; 18(10):e1611-e1620. PubMed ID: 35944229
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Chesney J; Lewis KD; Kluger H; Hamid O; Whitman E; Thomas S; Wermke M; Cusnir M; Domingo-Musibay E; Phan GQ; Kirkwood JM; Hassel JC; Orloff M; Larkin J; Weber J; Furness AJS; Khushalani NI; Medina T; Egger ME; Graf Finckenstein F; Jagasia M; Hari P; Sulur G; Shi W; Wu X; Sarnaik A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600653
[TBL] [Abstract][Full Text] [Related]
48. Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study.
Thiem A; Mashhadiakbar P; Cussigh C; Hassel JC; Grimmelmann I; Gutzmer R; Schlaak M; Heppt MV; Dücker P; Hüning S; Schulmeyer L; Schilling B; Haferkamp S; Ziemer M; Moritz RKC; Hagelstein V; Terheyden P; Posch C; Gaiser MR; Kropp P; Emmert S; Müller B; Tietze JK
J Eur Acad Dermatol Venereol; 2023 May; 37(5):884-893. PubMed ID: 36433671
[TBL] [Abstract][Full Text] [Related]
49. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
[TBL] [Abstract][Full Text] [Related]
50. Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI)
Safi M; Al-Azab M; Jin C; Trapani D; Baldi S; Adlat S; Wang A; Ahmad B; Al-Madani H; Shan X; Liu J
Front Immunol; 2021; 12():609728. PubMed ID: 34887846
[TBL] [Abstract][Full Text] [Related]
51. Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.
Woo TE; Stukalin I; Ding PQ; Goutam S; Sander M; Ewanchuk B; Cheung WY; Heng DYC; Cheng T
Curr Oncol; 2023 Sep; 30(10):8936-8947. PubMed ID: 37887546
[No Abstract] [Full Text] [Related]
52. Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab.
Goutam S; Stukalin I; Ewanchuk B; Sander M; Ding PQ; Meyers DE; Heng D; Cheung WY; Cheng T
Curr Oncol; 2022 Oct; 29(10):7695-7704. PubMed ID: 36290885
[TBL] [Abstract][Full Text] [Related]
53. Health care and socioeconomic costs for long-term survivors after implementation of checkpoint-inhibitors and targeted agents for metastatic melanoma.
Soerensen AV; Kjellberg J; Ibsen R; Bastholt L; Schmidt H; Svane IM
Eur J Cancer; 2023 Oct; 192():113288. PubMed ID: 37672816
[TBL] [Abstract][Full Text] [Related]
54. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
[TBL] [Abstract][Full Text] [Related]
55. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
56. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
[TBL] [Abstract][Full Text] [Related]
57. Real-World Evaluation of the Management, Treatment Pathways and Outcome of Melanoma Patients with Target Therapies in Italy.
Marcon IG; Valsecchi D; Durso L; Premoli E; Sangiorgi D; Perrone V; Catena L; Degli Esposti L
Adv Ther; 2023 Sep; 40(9):3875-3895. PubMed ID: 37368101
[TBL] [Abstract][Full Text] [Related]
58. Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.
Walker MS; Reyes C; Kerr J; Satram-Hoang S; Stepanski EJ
Int J Dermatol; 2014 Nov; 53(11):e499-506. PubMed ID: 24602078
[TBL] [Abstract][Full Text] [Related]
59. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.
Akturk HK; Couts KL; Baschal EE; Karakus KE; Van Gulick RJ; Turner JA; Pyle L; Robinson WA; Michels AW
JAMA Netw Open; 2022 Dec; 5(12):e2246400. PubMed ID: 36512357
[TBL] [Abstract][Full Text] [Related]
60. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
